Navigation Links
Study shows cost-effectiveness of smoking cessation counseling during hospitalization
Date:6/18/2014

OTTAWA, June 18, 2014 In a recent study published in Tobacco Control, researchers at the University of Ottawa Heart Institute have demonstrated the cost-effectiveness of the Ottawa Model for Smoking Cessation (OMSC), an intervention that includes in-hospital counseling, pharmacotherapy and post-hospital follow-up, compared to usual care among smokers hospitalized with acute myocardial infarction, unstable angina, heart failure, and chronic obstructive pulmonary disease.

The study examined patients hospitalized in Ontario, a province with a population of approximately 12.8 million. The smoking prevalence among Ontarians aged 15 years and older was 15.4% in 2009. The smoking prevalence among Canadian hospital populations is higher, at 20%. Consequently, on a given day in Ontario, approximately 6,400 of the province's 32,000 hospital beds are occupied by current smokers. Healthcare is publicly funded through the Ontario Health Insurance Plan, where medically necessary services including primary care and specialty care, hospital stays, diagnostic investigations and surgical procedures are available at no cost to residents. There are 211 hospital sites in Ontario that recorded an estimated 987,757 acute care inpatient admissions in 2009.

The study shows that from the hospital payer's perspective, delivery of the Ottawa Model for Smoking Cessation (OMSC) can be considered cost effective the program costs a mere $20 to help one person quit smoking, $103 to help patients avoid a day spent in hospital, $36 to gain one year of life, and $68 to gain one quality-adjusted (i.e., healthy) year of life. In the first year, the researchers calculated that provision of the OMSC to 15,326 smokers would generate 4,689 quitters, and would prevent 116 re-hospitalizations, 923 hospital days, and 119 deaths. Results were robust within numerous sensitivity analyses. An important consideration is the relatively low intervention cost compared to the reduction in costs related to readmissions for illnesses associated with continued smoking.

"Not surprisingly, these results indicate that the economic burden to the hospital system of continued smoking is significant," said Kerri-Anne Mullen, lead author and Network Manager for OMSC at the University of Ottawa Heart Institute. "Hospitalization is an opportune time to initiate smoking cessation treatment as smokers are frequent and high cost users of the healthcare system and are often highly motivated to quit smoking during their admission."

An estimated $547 million is spent each year in Ontario on hospitalizations for acute myocardial infarction, unstable angina, heart failure, and chronic obstructive pulmonary disease (COPD) alone. The study estimates that provision of the OMSC intervention to smokers admitted with these issues would represent 0.20% of this cost, yet could result in several individual and health system benefits and, in the case of COPD patients, could result in actual cost savings.


'/>"/>

Contact: Vincent Lamontagne
vlamontagne@ottawaheart.ca
613-761-4427
University of Ottawa Heart Institute
Source:Eurekalert

Related medicine news :

1. TGen and Scottsdale Healthcare begin study of new drug for patients with solid tumors
2. Gut bacteria predict survival after stem cell transplant, study shows
3. E-cigs heavily marketed on Twitter, study finds
4. Caffeine affects boys and girls differently after puberty, study finds
5. UTMB to participate in $30 million national study to prevent falls in older people
6. Moffitt study shows utilizing genetic health care professional reduces unnecessary testing
7. Virginia G. Piper Cancer Center vaccine study hopes to improve pancreatic cancer treatment
8. Charity funding study brings alcohol industry influence on UK policy into question
9. New study sheds light on what happens to cool kids
10. Breakthrough study sheds new light on best medication for children with seizures
11. Harvard study finds substance abuse & mental health problems in MSM interfere with HIV medication adherence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: